Xunming Biotech, a company focused on AI-driven antibody design, has secured $35 million in Series A+ funding. The round was led by Sequoia China with participation from MatrixPartners China and Boyuan Capital, alongside existing investors. Funds will be allocated to advancing their AuraIDE™ platform, enhancing foundation models and agent capabilities, and expanding their experimental facilities to streamline the drug discovery and development process. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
IMPACT Accelerates AI integration in drug discovery, potentially speeding up the development of novel therapeutics.
RANK_REASON Significant funding round for an AI-focused biotech company.